18.26
-1.13(-5.83%)
Currency In USD
| Previous Close | 19.39 |
| Open | 19.22 |
| Day High | 19.22 |
| Day Low | 17.98 |
| 52-Week High | 25 |
| 52-Week Low | 6.36 |
| Volume | 1.69M |
| Average Volume | 2.88M |
| Market Cap | 2.61B |
| PE | -5.04 |
| EPS | -3.62 |
| Moving Average 50 Days | 20.31 |
| Moving Average 200 Days | 13.84 |
| Change | -1.13 |
If you invested $1000 in Dyne Therapeutics, Inc. (DYN) since IPO date, it would be worth $764.02 as of January 09, 2026 at a share price of $18.26. Whereas If you bought $1000 worth of Dyne Therapeutics, Inc. (DYN) shares 5 years ago, it would be worth $678.81 as of January 09, 2026 at a share price of $18.26.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 07, 2026 12:30 PM GMT
WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that Jo
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors
GlobeNewswire Inc.
Dec 23, 2025 12:30 PM GMT
WALTHAM, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the app
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
GlobeNewswire Inc.
Dec 11, 2025 9:05 PM GMT
WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the clo